BioVie Inc.

2.50+0.1200+5.04%Vol 110.15K1Y Perf -69.33%
Aug 16th, 2022 16:00 DELAYED
BID2.50 ASK2.80
Open2.46 Previous Close2.38
Pre-Market- After-Market2.74
 - -  0.24 9.60%
Target Price
13.50 
Analyst Rating
Strong Buy 1.00
Potential %
440.00 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
16.77 
Earnings Rating
Market Cap62.23M 
Earnings Date
29th Aug 2022
Alpha0.02 Standard Deviation0.47
Beta2.06 

Today's Price Range

2.422.86

52W Range

1.338.33

5 Year PE Ratio Range

-24.20-6.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
21.95%
1 Month
39.66%
3 Months
-13.19%
6 Months
-24.01%
1 Year
-69.33%
3 Years
-75.03%
5 Years
-94.29%
10 Years
-

TickerPriceChg.Chg.%
BIVI2.500.12005.04
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.52-0.2846.15
Q02 2022-0.41-0.2246.34
Q02 2021-0.12-0.22-83.33
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date29th Aug 2022
Estimated EPS Next Report-0.42
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume110.15K
Shares Outstanding24.89K
Shares Float4.82M
Trades Count490
Dollar Volume288.35K
Avg. Volume39.94K
Avg. Weekly Volume31.41K
Avg. Monthly Volume37.16K
Avg. Quarterly Volume51.26K

BioVie Inc. (NASDAQ: BIVI) stock closed at 2.5 per share at the end of the most recent trading day (a 5.04% change compared to the prior day closing price) with a volume of 110.15K shares and market capitalization of 62.23M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. BioVie Inc. CEO is Terren S. Peizer.

The one-year performance of BioVie Inc. stock is -69.33%, while year-to-date (YTD) performance is -44.44%. BIVI stock has a five-year performance of -94.29%. Its 52-week range is between 1.325 and 8.33, which gives BIVI stock a 52-week price range ratio of 16.77%

BioVie Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 5.58, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -765.21%, a ROC of -893.55% and a ROE of -1 400.28%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BioVie Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. BioVie Inc.’s next earnings report date is 29th Aug 2022.

The consensus rating of Wall Street analysts for BioVie Inc. is Strong Buy (1), with a target price of $13.5, which is +440.00% compared to the current price. The earnings rating for BioVie Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioVie Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioVie Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.14, ATR14 : 0.18, CCI20 : 138.24, Chaikin Money Flow : 0.09, MACD : 0.06, Money Flow Index : 41.40, ROC : 8.68, RSI : 69.50, STOCH (14,3) : 85.07, STOCH RSI : 0.95, UO : 53.34, Williams %R : -14.93), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioVie Inc. in the last 12-months were: Joanne Wendy Kim (Buy at a value of $10 798)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BioVie Inc.

BioVie Inc is active in the healthcare domain in the United States. The company is a development stage enterprise engaged in the discovery, development, and commercialization of a therapy targeting ascites due to liver cirrhosis. Its therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis. BioVie is developing BIV201 for alleviating the portal hypertension and correcting splanchnic vasodilation, thereby increasing effective blood volume and reducing the signals to the kidneys to retain excess salt and water.

CEO: Terren S. Peizer

Telephone: +1 312 283-5793

Address: 2120 Colorado Avenue, Santa Monica 90404, CA, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

56%44%

Bearish Bullish

67%33%

Bearish Bullish

67%33%


News

Stocktwits